Table 3.
Age | Stage | Histology | Grade | LVSI | MI (%) | Lymph node metastasis | Adjuvant tx | Local recurrence | Distant recurrence | Time to recur (months) | Tx | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
58 | IIIC1 | Endometroid | 3 | Present | <50 | Present | CCRT | Right port | Nil | 9 | Excision and CT | NED |
58 | IA | Endometroid | 3 | Present | <50 | Absent | VBT | Nil | Malignant ascites | 18 | CT | DOD |
56 | IIIC2 | Serous | 3 | Present | >50 | Present | CCRT | Nil | Malignant ascites | 15 | CT | DOD |
60 | IB | Endometroid | 3 | Absent | >50 | Absent | EBRT | Nil | Right supraclavicular LN | 8 | Excision and CT | NED |
62 | IB | Endometroid | 3 | Present | <50 | Absent | EBRT | Nil | Right Lung | 10 | CT | DOD |
LVSI: Lymph-vascular space invasion, MI: Myometrial invasion, LN: Lymph node, tx: Treatment, Tx: Treatment after recurrence, CCRT: Sandwich chemoradiation, CT: Systemic chemotherapy, VBT: Vaginal brachytherapy, EBRT: External beam radiotherapy, NED: No evidence of disease, DOD: Died of disease